Isentress Approval History

• FDA approved: Yes (First approved October 12th, 2007)
• Brand name: Isentress
• Generic name: raltegravir
• Company: Merck & Co., Inc.
• Treatment for: HIV Infection

Isentress (raltegravir) is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

FDA Approval History for Isentress

Date	Article
Dec 21, 2011	FDA Expands Use of HIV Drug Isentress to Children and Adolescents
Feb  5, 2009	HIV/AIDS Update - Traditional Approval of Isentress (raltegravir)
Oct 12, 2007	FDA Approves of Isentress (raltegravir)
Oct 12, 2007	Impending FDA Approval Decision on the First HIV Integrase Inhibitor Isentress Can Have Significant Impact for Patients
Sep  6, 2007	FDA Advisory Committee Unanimously Recommends Accelerated Approval of Isentress (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV
Jun 27, 2007	FDA Priority Review Granted for Isentress (raltegravir), Merck's Investigational Integrase Inhibitor for HIV

See also...

Isentress (raltegravir) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.